NVCR

In October 2026, NovoCure's Optune Pax received approval in Japan for unresectable locally advanced pancreatic cancer, the company announced its third-quarter 2026 financial results, NVCR shares fell 3.0% contributing to a monthly decline, and Wall Street Zen downgraded NovoCure to a 'hold' rating. In September 2026, NovoCure announced unauthorized access to some of its information systems, exposing US patient records, and also announced upcoming investor events. In July 2026, NovoCure reported record second-quarter 2026 financial results with $183.6 million net revenue and an 18% increase in global active patients, raising its 2026 revenue guidance and improving its adjusted EBITDA outlook; the Pomerantz Law Firm announced an investigation into claims on behalf of investors; and Wedbush and H.C. Wainwright raised their price targets. In June 2026, the Phase 3 TRIDENT Trial failed to achieve its primary endpoint for overall survival in glioblastoma patients, causing shares to drop over 18%, but the company also received CE Mark approval for its Optune Pax device to treat locally advanced pancreatic cancer, with Germany becoming the first European launch market.